ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年12月27日 17時00分
Source:
Eisai
エーザイ、人事異動ならびに組織改編(2023年1月1日付)を発表
東京, 2022年12月27日 - (JCN Newswire) - エーザイは本日、人事異動ならびに組織改編(2023年1月1日付)を発表しました。
<2023年1月1日付 人事異動>
■ グローバル本社
新任務/旧任務/氏名
AD バリュー&アクセス企画部長/インテグレイティッドディメンシア ストラテジー部 バリュー部長/冨田 清行
<2023年1月1日付 主な組織改編>
■ グローバル本社
1.AD バリュー&アクセス企画部の新設
チーフエコシステムオフィサー直下に AD バリュー&アクセス企画部を新設する。AD バリュー&アクセス企画部は、日本・中国・アジアにおける AD 診断パスウェイやアクセス・価格戦略を担う。これに伴い、インテグレイテッドディメンシアストラテジー部 バリュー部は発展的に解組する。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202293.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI-AP Awarded Long-term Service Contract for the Garabogazkarbamid Fertilizer Plant in Turkmenistan
Jul 17, 2025 19:07 JST
Mitsubishi Motors Premieres the All-New Destinator in Indonesia
Jul 17, 2025 17:21 JST
Hitachi, global investment firm Brookfield, and global commodities trading firm Hartree Begin to Explore a Funding Scheme in the Environmentally-friendly Digital Infrastructure Sector
Jul 17, 2025 14:16 JST
"TOKIO Exciting Anime Workshop" Confirmed - Enjoy "Summer Festival at Anime Tokyo Station" This Summer Vacation
Jul 17, 2025 11:00 JST
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis
Jul 16, 2025 22:00 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Jul 16, 2025 14:50 JST
New Trains for Singapore's Sengkang-Punggol LRT Begin Commercial Operation
Jul 16, 2025 14:34 JST
AUG East Consortium and NEC to develop high-capacity submarine cable system across East Asia
Jul 16, 2025 14:00 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition - New Designs Added for Admission Bonus Illustration Cards
Jul 16, 2025 11:00 JST
Fujitsu Data Intelligence PaaS enhances Mazda's data-utilization and decision-making
Jul 16, 2025 10:30 JST
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection
Jul 16, 2025 10:20 JST
All Nippon Airways and Hitachi Unveil Japan's First Airline "Operations Brain" System, Enabling Rapid, Optimal Flight Schedule Revisions During Disruptions
Jul 15, 2025 12:00 JST
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
Hitachi develops "Metaverse Platform for Nuclear Power Plants" to enhance efficiency in construction and maintenance operations
Jul 09, 2025 19:02 JST
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program
Jul 08, 2025 20:30 JST
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
Jul 08, 2025 09:31 JST
More Latest Release >>
Related Release
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
7/16/2025 2:50:00 PM JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
7/14/2025 10:20:00 AM JST
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
7/8/2025 9:31:00 AM JST
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
6/2/2025 5:46:00 PM JST
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
5/28/2025 5:45:00 PM JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
5/21/2025 3:00:00 PM JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
5/16/2025 5:21:00 PM JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
More Press release >>